Successive AdCom wins for bluebird bio cue encouraging signs for rare disease gene therapies
It’s been a turbulent year for gene therapies targeting rare diseases. Could two recent votes for bluebird bio signal a change in fortune?
By
William Newton
William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, rare diseases, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
Latest articles
All Articles
Amylyx AdCom: panelists narrowly vote against FDA approval in ALS despite strong patient advocacy
Some FDA panelists cited concerns with the ALS trial design, while others pointed to positive data and the high…
By
Navigating distribution challenges for rare disease drugs
On Rare Disease Day, Pharmaceutical Technology explores how specialty pharmacies and value-based contracts could shape drug distribution.
By
Schizophrenia drug landscape: a stagnant field on the cusp of change?
Several pipeline therapies could shake up the schizophrenia field, but their road through development is unlikely to be an…
By
Most of Latin America, Caribbean left behind in Merck’s oral Covid-19 antiviral deal
Many upper middle-income countries fall between the cracks after a recent landmark contract opened molnupiravir access to 105 countries.
By
CyanVac eyes fundraise for parainfluenza-vectored Covid-19 vaccine after December data
CyanVac’s CVXGA1 is a nasally administered Covid-19 vaccine that uses a parainfluenza virus 5 vector.
By
Sage and Biogen’s depression drug iffy on efficacy despite dosing, safety upside
In a crowded antidepressant field, zuranolone’s fast onset and sustained effect might not be enough to mask its so-so…
By
Merck and Ridgeback’s molnupiravir rollout difficult to map in uncertain Covid-19 landscape
Questions about oral molnupiravir's deployment still loom large as clinicians await crucial late-stage trial results.
By
Oral molnupiravir has at least 350 patients left to recruit in Phase III Covid-19 trial
As breakthrough mild-to-moderate Covid-19 cases continue to rise, all eyes are on Merck and Ridgeback Biotherapeutics’ antiviral.
By